Form 8-K

8-K — Pulmatrix, Inc.

Accession: 0001493152-26-037592

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001574235

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001574235

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 13, 2026

PULMATRIX,

INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-36199

46-1821392

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

945

Concord Street, Suite 1217

Framingham,

MA 01701

(Address

of principal executive offices) (Zip Code)

(888)

355-4440

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of exchange on which registered

Common

Stock, par value $0.0001 per share

PULM

The

NASDAQ Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

August 13, 2026, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30,

2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by

reference.

accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being

furnished pursuant to Item 2.02, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated

by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act,

except as shall be expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release dated August 13, 2026*

104

Cover

Page Interactive Data File (formatted as Inline XBRL)

This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

PULMATRIX,

INC.

Date:

August 13, 2026

By:

/s/

Peter Ludlum

Peter

Ludlum

Interim

Chief Executive Officer and Interim Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Pulmatrix

Announces Second Quarter 2026 Financial Results and Progress on Merger

Form

S-4 filed related to the announced merger agreement with Eos SENOLYTIX

Framingham,

Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical

company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory

diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its second quarter financial

results for 2026 and provided a corporate update related to the merger agreement with Eos SENOLYTIX announced at the end of the first

quarter of 2026.

Peter

Ludlum, Interim Chief Executive Officer of Pulmatrix, commented,

“Our focus in the second quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX,

a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related

diseases using the MitoXcel™ platform. To that end, we have filed a Form S-4 in relation to the Merger.”

Proposed

Merger with Eos SENOLYTIX

previously reported, on March 26, 2026, the Company entered into an agreement (the “Merger Agreement”) and plan of merger

(the “Merger”) with Eos SENOLYTIX, Inc. (“Eos”). The proposed Merger is currently anticipated to close in the

third quarter of 2026, subject to customary closing conditions. If the proposed Merger is completed, the business of Eos will continue

as the business of the combined company.

connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase

agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred

Stock, raising aggregate gross proceeds of $1.0 million.

Additional

information about the Merger Agreement was previously disclosed in a registration statement on Form S-4 (File No. 333-297342) initially

filed with the Securities and Exchange Commission (the “SEC”) on July 9, 2026, as amended on August 3, 2026.

Pulmatrix

Seeks to Out-license or Monetize its Clinical Assets

iSPERSE™

Technology

● iSPERSE™,

also licensed to MannKind Corporation and Cipla Technologies for certain fields of use, utilizes

particles that are engineered with a small, dense and dispersible profile to exceed the performance

of traditional dry powder particles as the iSPERSE™ particles have the dispersibility

advantages of porous engineered particles. Pulmatrix believes this results in superior drug

delivery compared to traditional oral and injectable forms of treatment for certain diseases.

● As

of June 30, 2026, Pulmatrix’s patent portfolio related to iSPERSE™ included approximately

142 granted patents, 17 of which are U.S.-granted patents, plus approximately 49 pending

patent applications in the U.S. and other jurisdictions.

● In

July 2026, Pulmatrix was awarded a patent in India with claims encompassing PUR1900 resulting

from a patent hearing in India.

PUR1900

● PUR1900,

has been approved to proceed to a Phase 3 in India conducted by our partner Cipla. This is

the Company’s inhaled iSPERSE™ formulation of the antifungal drug itraconazole

being investigated for various indications. The Company and its partner, Cipla, wound down

a Phase 2b trial that the Company was operating in 2024. Cipla has continued clinical development

outside the United States, and in 2025 completed their Phase 2 study in India, published

positive results and has been approved by India’s Central Drug Standard Control Organization

to proceed with a Phase 3 clinical trial, which Cipla currently expects to commence in 2026.

● Pulmatrix

will receive 2% royalties on any potential future net sales by Cipla outside the United States

should Cipla successfully market PUR1900 outside the United States. Within the United States,

the Company and Cipla share the rights 50/50 and will seek to monetize PUR1900 for indications

where an orally inhaled antifungal may provide a therapeutic benefit or fulfill an unmet

medical need.

PUR3100

● PUR3100,

a Phase 2-ready asset, is an orally inhaled dihydroergotamine (“DHE”) engineered

with Pulmatrix’s iSPERSE™ dry powder inhalation technology for the treatment

of acute migraine has a Food and Drug Administration acceptance of an Investigational New

Drug (“IND”) application for PUR3100 and receipt of a “study may proceed”

letter to proceed with a Phase 2 study. The IND includes a Phase 2 clinical protocol where

safety and preliminary efficacy of PUR3100 will be investigated in patients with acute migraine.

● The

Phase 2 IND builds on the Phase 1 trial results of PUR3100, which were published in 2024

in the peer-reviewed publication, Headache: The Journal of Head and Face Pain. The

study showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time

to maximum concentration occurred at five minutes after dosing at all dosing levels. The

PUR3100 dose groups also showed a lower incidence of nausea and no vomiting compared to observations

of nausea and vomiting in the intravenously (“IV”) administered DHE dose group.

PUR1800

● PUR1800

is a Narrow Spectrum Kinase Inhibitor (“NSKI”), engineered with our iSPERSE™

technology, for the treatment of acute exacerbations in chronic obstructive pulmonary disease

(“AECOPD”). In 2023, Pulmatrix presented complete results from a Phase 1b study

of PUR1800 for AECOPD, indicating PUR1800 was well-tolerated with no observed safety signals.

The topline data, along with the results from chronic toxicology studies, support the continued

development of PUR1800 for the treatment of AECOPD and other inflammatory respiratory diseases.

● In

2024, Pulmatrix published an abstract titled “Ex vivo evaluation of the potential

for Narrow Spectrum Kinase inhibitors as a treatment for Idiopathic Pulmonary Fibrosis”.

Second

Quarter 2026 Financial Results

Research

and development expenses were less than $0.1 million for both the three months ended June 30, 2026, and 2025. All clinical development

is currently on hold while the Company works to license or monetize our clinical assets.

General

and administrative expenses decreased approximately $0.5 million to $1.0 million for the three months ended June 30, 2026, compared to

$1.5 million for the three months ended June 30, 2025. The decrease was primarily due to lower costs incurred related to software subscriptions,

legal and patent costs, and business development and merger-related activities.

The

Company’s total cash and cash equivalents balance as of June

30, 2026, was $2.2 million, in addition to $0.7 million in restricted cash that would become unrestricted

following consummation of the Merger, as compared to $4.1 million as of December 31, 2025. The Company’s unaudited financial statements

were prepared assuming that the Company will continue as a going concern within one year after the date such financial statements are

issued. The Company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is

sufficient to fund its operations at least through the anticipated closing of the proposed Merger with Eos.

PULMATRIX,

INC.

Consolidated

Balance Sheets

(in

thousands, except share and per share data)

June 30,

2026

December 31,

2025

(unaudited)

Assets

Current assets:

Cash and cash equivalents

$ 2,168

$ 4,088

Restricted cash

700

Prepaid expenses and other current assets

371

Total current assets

3,239

4,129

Long-term restricted cash

Total assets

$ 3,246

$ 4,139

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$ 529

$ 272

Accrued expenses and other current liabilities

160

Total current liabilities

689

329

Total liabilities

689

329

Stockholders’ equity:

Preferred stock, $0.0001 par value — 500,000 shares authorized;

6,746 shares designated Series A Convertible Preferred Stock: no shares issued and outstanding at June 30, 2026 and December 31, 2025;

1,100 shares designated Series B Convertible Preferred Stock: 1,000 shares issued and outstanding at June 30, 2026, and no shares issued and outstanding at December 31, 2025

966

Common stock, $0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at June 30, 2026, and December 31, 2025

Additional paid-in capital

306,117

306,128

Accumulated deficit

(304,526 )

(302,318 )

Total stockholders’ equity

2,557

3,810

Total liabilities and stockholders’ equity

$ 3,246

$ 4,139

PULMATRIX,

INC.

Consolidated

Statements of Operations

(in

thousands, except share and per share data)

(unaudited)

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Operating expenses:

Research and development

$ 2

$ 14

$ 5

$ 33

General and administrative

1,044

1,534

2,333

3,362

Total operating expenses

1,046

1,548

2,338

3,395

Loss from operations

(1,046 )

(1,548 )

(2,338 )

(3,395 )

Other income (expense):

Interest income

Fair value adjustment of warrants

Other income (expense), net

(43 )

108

(123 )

Total other income (expense), net

(1 )

130

Net loss

$ (1,036 )

$ (1,549 )

$ (2,208 )

$ (3,357 )

Dividends accrued on Series B Convertible Preferred Stock

(16 )

Net loss attributable to common stockholders

(1,052 )

(1,549 )

(2,224 )

(3,357 )

Net loss per share attributable to common stockholders – basic and diluted

$ (0.29 )

$ (0.42 )

$ (0.61 )

$ (0.92 )

Weighted average common shares outstanding – basic and diluted

3,652,285

About

Pulmatrix, Inc.

Pulmatrix

is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat

migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s

proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and

serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis

(“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™,

which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve

patient outcomes. For more on the Company’s inhaled product candidates please visit:

https://www.pulmatrix.com/pipeline.html.

About

Eos SENOLYTIX, Inc.

Eos

SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying

biological mechanisms of aging. Eos’s lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides,

have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target,

the mitochondrial membrane potential (MMP), also called the “Δψm”. These two mechanisms include (1) the return

of the efficiency of mitochondrial. Merger-associated financings are expected to support advancement of the combined company’s

pipeline through key clinical milestones. Eos is led by Kevin Slawin, M.D., Founder and Chief Executive Officer, a physician-scientist

and serial biotechnology entrepreneur with decades of experience in translational medicine, drug development, and company formation.

Dr. Slawin was the founder of Bellicum Pharmaceuticals, Inc., an early pioneer in CAR T cell therapies, and has founded and is currently

leading multiple life sciences ventures focused on aging biology and mitochondrial therapeutics. He is supported by a team of experienced

biotechnology executives, scientists, and advisors with prior leadership roles at major pharmaceutical companies, academic medical centers,

and emerging biotechnology firms. For more information, visit https://www.eossenolytix.com.

Forward-Looking

Statements

Certain

statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within

the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical

fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,”

“could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,”

“is confident that,” “may,” “plans,” “seeks,” “projects,” “targets,”

and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking

statements are based on the beliefs of management as well as assumptions made by and information currently available to management and

include, but are not limited to, the use of proceeds from the private placement and conversion of the Series B Preferred Stock. Actual

results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including,

but not limited to, the consummation of any other potential reverse merger transaction in the future, among others; the Company’s

ability to divest its clinical assets on terms favorable to the Company, or at all, the Company’s ability to maintain compliance

with the listing standards of the Nasdaq Capital Market; the Company’s ability to continue as a going concern, the Company’s

ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish

that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations

on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential

products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially

reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third

parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and

enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including

risks and uncertainties with respect to the Company, including the proposed Merger with Cullgen, is set forth in the Company’s

filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or

amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or

obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required

by law.

Investor

Contact:

Chuck

Padala

Managing

Director

LifeSci

Advisors

646-627-8390

chuck@lifesciadvisors.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (3211 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-36199

Entity Registrant Name

PULMATRIX,

INC.

Entity Central Index Key

0001574235

Entity Tax Identification Number

46-1821392

Entity Incorporation, State or Country Code

Entity Address, Address Line One

945

Concord Street

Entity Address, Address Line Two

Suite 1217

Entity Address, City or Town

Framingham

Entity Address, State or Province

Entity Address, Postal Zip Code

01701

City Area Code

(888)

Local Phone Number

355-4440

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

PULM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration